Skip to main content

Yuxing Li, PhD

Academic Title:

Associate Professor

Primary Appointment:

Microbiology and Immunology

Location:

9600 Gudelsky Drive Rockville, MD 20850

Phone (Primary):

240-314-6332

Phone (Secondary):

410-706-7110

Education and Training

1985-1989: B.S. - Sichuan University, Chengdu, Sichuan, China (Genetics)

1989-1992: M.S. - Sichuan Industrial Institute of Antibiotics, The State Food and Drug Administration (SFDA), Chengdu, China (Microbiology)

1992-1996: Ph.D. - Iowa State University, Ames, IA (Genetics)

Biosketch

Dr. Yuxing Li obtained her PhD degree from Iowa State University majored in Genetics. After a postdoc training under the supervision of Dr. Susan Carpenter at Iowa State University on lentivirus pathogenesis and persistence, she joined Dr. Richard T. Wyatt’s laboratory in the Vaccine Research Center (VRC), NIAID/NIH as a research fellow.  At VRC, Dr. Li interacted and worked closely with scientists working on HIV structural biology, virology, and immunology, including Peter Kwong, Mark Connors, Mario Roederer, and John Mascola.  During the training at VRC, Dr. Li started to develop an integrated research program focused on HIV vaccine rational design based on HIV envelope glycoprotein structural and immunologic analysis.  In 2010, Dr. Li joined the IAVI Neutralizing Antibody Center at The Scripps Research Institute as an Assistant Professor of Immunology, based in La Jolla, California. In 2014, Dr. Li relocated her laboratory to the Institute for Bioscience and Biotechnology Research (IBBR) in Rockville, Maryland and affiliated with Department of Microbiology and Immunology, University of Maryland School of Medicine.

Research/Clinical Keywords

HIV-1, neutralizing antibody, B cell, Ebola virus, vaccine, immunotherapeutics, structural biology

Highlighted Publications

Steinhardt JJ, Guenaga J, Turner HL, McKee K, Louder MK, O’Dell S, Chiang CI, Lei L, Galkin A, Andrianov AK, Doria-Rose N, Bailer RT, Ward AB, Mascola JR, Li Y. Rational Design of a Trispecific Antibody Targeting the HIV-1 Env with Elevated Anti-viral Activity. Nature Communications.(2018). 9, 877. PMID: 29491415. PMCID: PMC5830440.

Zhao X*, Howell KA*, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y#, Aman MJ#. Immunization-elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell. (2017). 169, 891-904.e15. (# Co-correspondence author). PMID:28525756.

Wang Y, Sundling C, Wilson R, O'Dell S, Chen Y, Dai K, Phad GE, Zhu J, Xiao Y, Mascola JR, Karlsson Hedestam GB, Wyatt RT, Li Y. (2016). High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. Journal of Immunology. 196, 3729-43. PMID: 27001953.

Kong L*, Ju B*, Chen Y*, He L*, Ren L*, Liu J*, Hong K, Su B, Wang Z, Ozorowski G, Ji X, Hua Y, Chen Y, Deller MC, Hao Y, Feng Y, Garces F, Wilson R, Dai K, O'Dell S, McKee K, Mascola JR, Ward AB, Wyatt RT, Li Y#, Wilson IA#, Zhu J#, Shao Y#. (2016). Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Immunity, 44, 939-950.  (#, Co-senior authors). PMID: 27067056.

Wu X*, Yang Z-Y*, Li Y*, Hogerkorp C-M, Schief W, Seaman M.S, Zhou T, Schmidt S, Wu L, Xu L, Longo N, McKee K, O’Dell S, Louder MK,Wycuff D, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. (2010). Rational Design of Envelope Surface Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 329, 856-861. (*Co-first authors). PMCID: PMC2965066.

Li, Y., Migueles, S., Welcher, B., Svehla, K., Phogat, A., Louder, M.K., Wu, X., Shaw, G.M., Connors, C., Wyatt, R*., and Mascola, J.R*. (2007). Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nature Medicine, 13, 1032-1034. PMCID: PMC2584972.

Additional Publication Citations

A full list of Dr. Li's published work can be accessed by clicking here.

Research Interests

The long-term research interests of my lab include B cell response to viral infection, HIV-1 vaccine development and HIV pathogenesis and anti-viral therapy. Current, research efforts focus on investigating the development of B cell response targeting HIV envelope glycoproteins (Env) and searching for novel immunogen and immunization regimens to better elicit broadly neutralizing antibodies. Such studies aim to develop a better understanding of the mechanism underlying protective immunity and contribute to the development of a broadly effective HIV-1 vaccine. Rational design of Env immunogens and immunization regimens based on the B cell response analysis are actively progressing in my lab. Research on the reconstitution of immunity after anti-viral therapy and novel anti-viral approach development is also ongoing.

Therapeutic antibodies for Ebola virus infection had protection breadth limited to Zaire Ebola strain, but not effective for other pathogenic strains such as Sudan and Bundibugyo.   Recently, we successfully isolated broadly neutralizing antibodies from Ebola virus experiment vaccine immunized non-human primate animal and developed a pan-Ebolavirus therapeutic antibody cocktail for pre-clinical trial in non-human primate model. Future work will focus on delineating B cell response to the filovirus glycoproteins to inform vaccine design aimed to elicit broadly protective antibody response.

Awards and Affiliations

 

2012

 

 

2010

Center for AIDS Research (CFAR) Young Investigator Award, CFAR at University of California at San Diego

 

Merit Award, National Institute of Allergy and Infectious Diseases, National Institutes of Health

 

2007  

 

Staff Exceptional Performance Award, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health

 

2003

 

NIH Fellow Award for Research Excellence

 

1995 & 1996

 

Joan Stadlar Research Fellowship, Iowa State University

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Grants and Contracts

R01 AI126587                                                              

04/01/2017-03/31/2022

NIH/NIAID

Evolution of anti-filovirus B cell responses and mechanisms of protection

In this proposal, we seek to study the response of monkeys and humans to filovirus vaccines to determine the features of a vaccine response that would protect against all filoviruses. The proposed study is also likely to generate novel immunotherapeutic antibodies for treatment of filovirus infections.

MPI: Aman/ Li. Role: MPI; 25% effort

 

P01AI104722                                                                  

04/01/2014-03/31/2019

NIH/NIAID

High resolution analysis of Env-directed B cells to accelerate vaccine design

This grant is designed to isolate and characterize novel HIV vaccine elicited Env-specific antibodies.

PD: Richard Wyatt. Role: Project PI; 20% effort       

 

R01 AI102766                                                                

01/01/2013-12/31/2018 (no cost extension)

NIH/NIAID                                                         

High-resolution definition of B cell responses to HIV Env for Immunogen design

This grant is designed to analyze antibodies that induce recognition by known broadly neutralizing antibodies such as the CD4 binding site antibody, VRC01, and to then use these inducing antibodies as immune complex with HIV envelope glycoproteins to elicit neutralizing antibodies in small animal models.

PI: Yuxing Li. Role: PI; 25% effort

 

2017-MII-3992                                                               

09/08/2017-05/09/2018

Maryland Innovation Initiative

Next Generation Multi-Specific Antibody Therapeutic

This grant aims to develop multi-specific antibodies that combines the antigen binding regions from multiple HIV broadly neutralizing antibodies to achieve profoundly improved virus neutralization capacities.

PI: Yuxing Li. Role: PI; 10% effort

Professional Activity

NIH, Clinical Research and Field Studies of Infectious Diseases (CRFS) Study Section (2017)

NIH, AIDS-Associated Opportunistic Infections and Cancer (AOIC) study section (2017)

NIH, Special Emphasis Panel (ZRG1 IMM-T (02)) (2017)

AIDS Fond Reviewer, The Netherland (2015)

Reviewer for Journal of Clinical Investigation, Journal of Virology, Retrovirology, PLOS ONE, Scientific Reports, and Nature Communications

American Association of Immunologists, member

American Society for Virology, member

Links of Interest

Dr. Li's profile at IBBR:

https://www.ibbr.umd.edu/profiles/yuxing-li